Ciba-Geigy's calcitonin
Executive Summary
Firm's Cibacalcin, approved Oct. 31, is the first synthetic human calcitonin to clear FDA. The product will be available Dec. 1 at a price to wholesalers of $28.95. It is indicated for treatment of symptomatic Paget's disease of the bone. Ciba-Geigy said that unlike currently available calcitonin products, which are derived from salmon, the synthetic human product does not produce an antibody immune response.